Chemistry:CT-868
From HandWiki
CT-868 is an experimental "biased dual GLP-1 and GIP receptor modulator that exhibits no arrestin coupling or receptor internalization at either receptor". It is developed by Carmot Therapeutics for diabetes and obesity. The drug is taken by subcutaneous injection.[1][2][3][4]
References
- ↑ "CT 868". 7 August 2025. https://adisinsight.springer.com/drugs/800053575.
- ↑ "Efficacy and safety of CT-868, a novel, fully biased, dual glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor agonist, in type 2 diabetes: A double-blind, randomized placebo controlled phase 2 trial". Diabetes Obes Metab 28 (3): 1673–1682. March 2026. doi:10.1111/dom.70006. PMID 40762050.
- ↑ Chakravarthy, Manu; Hernandez, Moises; Elliott, Michael; Macias, Alejandra; Hansen, Stig K.; Hompesch, Marcus (20 June 2023). "774-P: Weight-Independent Effects of CT-868, a Signaling Biased Dual GLP-1/GIP Receptor Modulator, on Glucose Homeostasis in Overweight and Obese Adults with Type 2 Diabetes". Diabetes 72 (Supplement_1). doi:10.2337/db23-774-P.
- ↑ Rodriguez, Ruben; Tracy, Ted; Morales, Marikris; Hergarden, Anne; Lam, Davina; Krishnan, Shyam; Hansen, Stig K.; Chakravarthy, Manu (20 June 2023). "1649-P: Biased GLP-1 Improves Weight Loss with Additional Benefits on Glucose Homeostasis via Biased GIP in Diabetic Rodent Models". Diabetes 72 (Supplement_1). doi:10.2337/db23-1649-P.
 |  |
